← Back to Screener
Apogee Therapeutics, Inc. Common Stock (APGE)
Price$90.92
Favorite Metrics
Price vs S&P 500 (26W)66.97%
Price vs S&P 500 (4W)30.12%
Market Capitalization$6.41B
All Metrics
Book Value / Share (Quarterly)$13.21
P/TBV (Annual)6.13x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.40
Price vs S&P 500 (YTD)18.01%
EPS (TTM)$-4.22
10-Day Avg Trading Volume0.68M
EPS Excl Extra (TTM)$-4.22
EPS (Annual)$-4.22
ROI (Annual)-25.41%
Cash / Share (Quarterly)$10.68
ROA (Last FY)-24.16%
EBITD / Share (TTM)$-4.68
Cash Flow / Share (Annual)$-2.97
P/B Ratio7.09x
P/B Ratio (Quarterly)5.71x
Net Income / Employee (Annual)$-0
ROA (TTM)-34.87%
EPS Incl Extra (Annual)$-4.22
Current Ratio (Annual)18.55x
Quick Ratio (Quarterly)26.19x
3-Month Avg Trading Volume1.03M
52-Week Price Return187.77%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.52
52-Week High$95.31
EPS Excl Extra (Annual)$-4.22
26-Week Price Return75.72%
Quick Ratio (Annual)18.29x
13-Week Price Return11.85%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)26.57x
Enterprise Value$6,274.991
Revenue / Employee (Annual)$0
Cash / Share (Annual)$8.97
3-Month Return Std Dev66.32%
Net Income / Employee (TTM)$-0
ROE (Last FY)-25.41%
EPS Basic Excl Extra (Annual)$-4.22
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.22
ROI (TTM)-36.77%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.98
Price vs S&P 500 (52W)152.67%
Year-to-Date Return22.15%
5-Day Price Return6.29%
EPS Normalized (Annual)$-4.22
Month-to-Date Return9.54%
EBITD / Share (Annual)$-4.68
EPS Basic Excl Extra (TTM)$-4.22
P/TBV (Quarterly)2.13x
P/B Ratio (Annual)3.70x
Book Value / Share (Annual)$12.35
Price vs S&P 500 (13W)8.99%
Beta0.86x
Revenue / Share (TTM)$0.00
ROE (TTM)-36.77%
52-Week Low$31.38
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.45
4.32
4.32
4.26
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
APGEApogee Therapeutics, Inc. Common Stock | — | — | — | — | $90.92 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Apogee Therapeutics develops engineered monoclonal antibodies targeting atopic dermatitis, COPD, and other inflammatory and immunology indications with significant unmet medical need. The company's differentiated programs leverage optimized antibody engineering to overcome limitations of existing therapies by targeting validated mechanisms of action.